CXCL13 and neoplasm: compared the pre‐ and post‐treatment CD8+ T cells based on single‐cell RNA sequencing (scRNA‐seq) datasets from different tumor types and demonstrated that PD‐1/PD‐L1 blockade induces increased CXCL13+ TEXprog cells in responsive melanoma and non‐small cell lung cancer (NSCLC), but not in responsive skin basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), where TEXterm cells accounted for the majority of post‐treatment tumor‐infiltrating T cells.[39] This variable pattern may be attributed to different levels of immunosuppression in the TME.